195 related articles for article (PubMed ID: 23844722)
1. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.
Gilbreath JJ; Semino-Mora C; Friedline CJ; Liu H; Bodi KL; McAvoy TJ; Francis J; Nieroda C; Sardi A; Dubois A; Lazinski DW; Camilli A; Testerman TL; Merrell DS
Orphanet J Rare Dis; 2013 Jul; 8():105. PubMed ID: 23844722
[TBL] [Abstract][Full Text] [Related]
2. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
Semino-Mora C; Liu H; McAvoy T; Nieroda C; Studeman K; Sardi A; Dubois A
Ann Surg Oncol; 2008 May; 15(5):1414-23. PubMed ID: 18299935
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution.
Semino-Mora C; Testerman TL; Liu H; Whitmire JM; Studeman K; Jia Y; McAvoy TJ; Francis J; Nieroda C; Sardi A; Merrell DS; Dubois A
Clin Cancer Res; 2013 Jul; 19(14):3966-76. PubMed ID: 23743566
[TBL] [Abstract][Full Text] [Related]
4. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
5. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
Choudry HA; Mavanur A; O'Malley ME; Zeh HJ; Guo Z; Bartlett DL
Ann Surg Oncol; 2012 May; 19(5):1402-9. PubMed ID: 22302271
[TBL] [Abstract][Full Text] [Related]
6. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei.
Hiraide S; Komine K; Sato Y; Ouchi K; Imai H; Saijo K; Takahashi M; Takahashi S; Shirota H; Takahashi M; Ishioka C
Int J Clin Oncol; 2020 Apr; 25(4):774-781. PubMed ID: 31823151
[TBL] [Abstract][Full Text] [Related]
8. Pre- and post-operative antibiotics in conjunction with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) should be considered for pseudomyxoma peritonei (PMP) treatment.
Merrell DS; McAvoy TJ; King MC; Sittig M; Millar EV; Nieroda C; Metcalf JL; Blum FC; Testerman TL; Sardi A
Eur J Surg Oncol; 2019 Sep; 45(9):1723-1726. PubMed ID: 30770164
[TBL] [Abstract][Full Text] [Related]
9. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Int J Cancer; 2014 Jan; 134(2):478-86. PubMed ID: 23843173
[TBL] [Abstract][Full Text] [Related]
10. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
[TBL] [Abstract][Full Text] [Related]
11. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.
Amini A; Masoumi-Moghaddam S; Ehteda A; Morris DL
Orphanet J Rare Dis; 2014 May; 9():71. PubMed ID: 24886459
[TBL] [Abstract][Full Text] [Related]
12. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
13. Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.
Hotta M; Minamimoto R; Gohda Y; Igari T; Yano H
Eur Radiol; 2019 Oct; 29(10):5709-5716. PubMed ID: 30874878
[TBL] [Abstract][Full Text] [Related]
14. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis.
Ronnett BM; Yan H; Kurman RJ; Shmookler BM; Wu L; Sugarbaker PH
Cancer; 2001 Jul; 92(1):85-91. PubMed ID: 11443613
[TBL] [Abstract][Full Text] [Related]
15. Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP).
Pillai K; Akhter J; Mekkawy A; Chua TC; Morris DL
Int J Med Sci; 2017; 14(1):18-28. PubMed ID: 28138305
[No Abstract] [Full Text] [Related]
16. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
17. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
Bibi R; Pranesh N; Saunders MP; Wilson MS; O'dwyer ST; Stern PL; Renehan AG
Br J Cancer; 2006 Nov; 95(9):1258-64. PubMed ID: 17031402
[TBL] [Abstract][Full Text] [Related]
18. [Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei].
Deraco M; Kusamura S; Gronchi A
Tumori; 2003; 89(4 Suppl):54-5. PubMed ID: 12903545
[TBL] [Abstract][Full Text] [Related]
19. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]